Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 85,859 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Healthy Aging, Multivitamin and Mineral Supplementation
Interventions: MVM Core Blend, MVM Gold Blend, Placebo; Dietary Supplement
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years to 60 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Ulcerative Colitis (UC), Crohn's Disease
Interventions: Risankizumab, Cytochrome P450 (CYP) Substrates; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Coronado, California • DeLand, Florida • Margate, Florida + 1 more

Conditions: Pharmacokinetics, Bioavailability
Interventions: Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Glendale, California

Conditions: Scar
Interventions: Laser treatment; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Miami, Florida • Plantation, Florida

Conditions: Acne Vulgaris
Interventions: NB01, Vehicle Control; Biological · Other
Lead sponsor: Naked Biome, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: San Diego, California • Arlington, Texas • Austin, Texas

Conditions: Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions: Arm 1; Procedure
Lead sponsor: MD Stem Cells; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 2
States / cities: Westport, Connecticut • Coral Springs, Florida

Conditions: End Stage Renal Disease
Interventions: Nepro nutritional supplement, placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Rheumatoid Arthritis
Interventions: peficitinib, methotrexate; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Anniston, Alabama

Conditions: Pediatric Cancer, Adolescent and Young Adult Cancer
Interventions: ReSPECT; Behavioral
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 15 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Advanced Cancer
Interventions: PF-05212384, PD-0325901, irinotecan; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 15
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 3 more

Conditions: Breast Cancer, Depression
Interventions: Mindfulness (MAPs) Live Online, Mindfulness (MAPs) Digital App, Meditation Only Control Group; Behavioral
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years to 50 Years
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 381
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 317 more

Conditions: Macular Edema
Interventions: Ranibizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Paducah, Kentucky • Charlotte, North Carolina • Chattanooga, Tennessee + 1 more

Conditions: Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions: Anti-OX40 Antibody PF-04518600, Axitinib, Laboratory Biomarker Analysis, Placebo; Biological · Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • Newport Beach, California • Sacramento, California + 5 more

Conditions: Tumor, Ovarian Cancer
Interventions: NKTR-102 q14d, NKTR-102 q21d; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 11
States / cities: Highland, California • Los Angeles, California • Newport Beach, California + 8 more

Conditions: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: gemcitabine, Cisplatin, Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Relapsed and/or Refractory Multiple Myeloma
Interventions: BMS-986453, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 13
States / cities: Birmingham, Alabama • Duarte, California • San Francisco, California + 8 more

Conditions: Head and Neck Cancer
Interventions: cisplatin, fluorouracil, adjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions: ixabepilone, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
Interventions: Placebo, SeVRSV Vaccine; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation
Interventions: IFN-gamma-secreting HAdV antigen specific T cells; Biological
Lead sponsor: Mari Dallas; Other
Eligibility: 3 Months and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy Volunteers
Interventions: PF-03882845 or Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Uterine Cancer
Interventions: Letrozole, Everolimus; Drug
Lead sponsor: Greater Baltimore Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma in Children
Interventions: Access to Asma Guardian website/app, Delayed Access to Asma Guardian website/app; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 5 Years to 12 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: vorinostat, anastrozole, letrozole, exemestane, positron emission tomography, F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, laboratory biomarker analysis; Drug · Procedure · Radiation + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Multivitamin and Mineral Supplementation and Healthy Aging

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers

Evaluation of Non-Ablative Laser for Treatment of Direct Brow Lift Scars

A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne

Stem Cell Ophthalmology Treatment Study II

Complementary Intradialytic Nutritional Supplementation in Dialysis Patients

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis

Improving Communication Between AYA Oncology Patients and Clinicians: A Patient-Centered Intervention

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

E-Mindfulness Approaches for Living After Breast Cancer

A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer

A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer

Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation

A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers

Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation

A Culturally Tailored Scalable Asthma Intervention for Hispanic Children (Asthma Guardian)

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy